PF-03654746
PF-03654746
PF-03654746 (/piː ɛf ˈzɪəroʊ ˈθriː ˈsɪks ˈfaɪv ˈfɔːr ˈsɪks/) is a pharmacological compound developed by Pfizer. It is a selective H3 receptor antagonist/inverse agonist.
Etymology
The name "PF-03654746" is a unique identifier given by the pharmaceutical company Pfizer. The "PF" stands for Pfizer, while the numbers "03654746" are a unique code assigned to the compound during its development.
Pharmacology
PF-03654746 is a potent and selective antagonist/inverse agonist of the H3 receptor. This receptor is primarily found in the central nervous system and plays a key role in the regulation of neurotransmitter release. By blocking this receptor, PF-03654746 can potentially modulate the release of several neurotransmitters, including acetylcholine, histamine, and norepinephrine, which may have therapeutic effects in various neurological disorders.
Clinical Trials
PF-03654746 has undergone clinical trials for the treatment of ADHD and Alzheimer's disease. However, the results of these trials have not led to the approval of the compound for these indications.
Related Terms
- Pfizer
- Histamine H3 receptor
- Central nervous system
- Neurotransmitter
- Acetylcholine
- Histamine
- Norepinephrine
- Neurological disorders
- Attention deficit hyperactivity disorder
- Alzheimer's disease
External links
- Medical encyclopedia article on PF-03654746
- Wikipedia's article - PF-03654746
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski